Summary

Home About Us Our Science Pipeline Mesothelioma Awareness Investors Media Contact A2B Antagonist - A2A Antagonist Targeted Adenosine Receptor Blockade Cyncado Therapeutics is a clinical stage biotech company advancing investigational A2B receptor antagonism and co-administered A2BA2A adenosine receptor blockade for mesothelioma and other cancers with high unmet medical need.50 Granted Patents Across Global Jurisdictions 3 Clinical Assets 3 Therapeutic Areas 15 World-Leading Experts Cyncado is advancing a differentiated adenosine oncology platform supported by 50 granted patents across global jurisdictions, multiple clinical-stage assets, priority cancer indications, and experienced scientific and global clinical leaders focused on mesothelioma and other cancers with high unmet medical need.

Title

Cyncado Therapeutics

Description

Clinical-stage biotech advancing investigational A2B and co-administered A2B/A2A adenosine receptor antagonist therapies for mesothelioma and other high unmet-need cancers.

Keywords

mesothelioma, adenosine, receptor, science, pipeline, awareness, antagonist, blockade, therapeutics, stage, cancers, high, medical, need, multiple, patents, jurisdictions

NS Lookup

A 216.150.1.1

Dates

Created 2026-08-12

Updated 2026-08-12

Summarized 2026-08-12